RIPK3 as a potential therapeutic target for Gaucher's disease. - Wikidata - thesis-toulmin - TriplyDB

RIPK3 as a potential therapeutic target for Gaucher's disease.

RIPK3 as a potential therapeutic target for Gaucher's disease.

http://www.wikidata.org/entity/Q54383542

about

An outline of necrosome triggers The clinical management of Type 2 Gaucher disease Programmed necrosis in the cross talk of cell death and inflammation The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance.Mitochondrial dysfunction associated with glucocerebrosidase deficiency Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease.Gaucher-Associated Parkinsonism.Astrocytes and lysosomal storage diseases.Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death.Glycosphingolipids and cell death: one aim, many ways Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis.Lysosomal Storage Diseases-Regulating Neurodegeneration.Necroptosis in Niemann-Pick disease, type C1: a potential therapeutic target.Therapeutic hypothermia attenuates tissue damage and cytokine expression after traumatic brain injury by inhibiting necroptosis in the rat.Induction of the type I interferon response in neurological forms of Gaucher disease CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease.Distinct Kinase-Independent Role of RIPK3 in CD11c+ Mononuclear Phagocytes in Cytokine-Induced Tissue Repair Sphingolipid lysosomal storage disorders.Emerging therapeutic targets for Gaucher disease.Lysosomal membrane permeabilization in cell death: new evidence and implications for health and disease.Neuroinflammation as modifier of genetically caused neurological disorders of the central nervous system: Understanding pathogenesis and chances for treatment.RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.New Directions in Gaucher Disease.Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.The Inflammatory Signal Adaptor RIPK3: Functions Beyond Necroptosis.The MLKL Channel in Necroptosis Is an Octamer Formed by Tetramers in a Dyadic Process.Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice.Necroptosis in neurodegenerative diseases: a potential therapeutic target.Delineating pathological pathways in a chemically induced mouse model of Gaucher disease.RIP3 deficiency ameliorates inflammatory response in mice infected with influenza H7N9 virus infection.Neuroprotective effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-β 1-42 induced neurotoxicity and memory impairment.Failure to Inactivate Nuclear GSK3β by Ser389-Phosphorylation Leads to Focal Neuronal Death and Prolonged Fear Response.RIP3 deficiency exacerbates inflammation in dextran sodium sulfate-induced ulcerative colitis mice model.Altered lysosome distribution is an early neuropathological event in neurological forms of Gaucher disease.Propagation of errors in citation networks: a study involving the entire citation network of a widely cited paper published in, and later retracted from, the journal Nature.RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase.

P2860

Q26751108-81B447F8-3DC8-498B-A37B-B9782B5676A8 Q26825082-AD823D3D-F36F-45B8-8A5B-79E356E62FFE Q27026709-85FE5BD9-095B-4E4C-9404-41BF9ACBB6B6 Q27313354-13FFD211-D97C-4D78-A076-0F352F412026 Q28115678-0D67491A-206E-4142-BC42-44258C43D380 Q28548589-1C233E57-CED4-4543-849B-8393EA01B8FD Q30367337-B404CA05-5CFA-4726-968F-DC34A2CED82D Q35180647-43945F76-5006-446F-8606-887F5911644A Q35851610-829914F9-69BB-4B7E-B98F-5D2479589EF3 Q36332588-E784E512-49C8-4082-8108-D85BC97D500D Q36347249-622F6CEE-263F-4C96-8FC0-17AFE57E451B Q36405917-2A0AC46B-08FB-4065-9B57-DB4D04592E00 Q36751262-55BDEA60-B59D-45FD-8007-77B0112FABCB Q36771137-BE6A9AC0-A776-40B5-AADD-DAFB81313839 Q36774925-7D33FD8C-2537-4DAB-896F-CF592E0D8CAC Q36799655-D62583DD-DF63-488E-AE8B-FAF9AD34863E Q36898538-4F7B5B40-8C87-44C3-AFC4-AB31E01C5956 Q37043500-3AA3AC46-7BF7-4B3C-8305-E9EE981F270E Q37353986-272D7184-9AAD-44AA-B8C7-165931A82391 Q37604580-10DEF94F-CDE4-44C1-AB56-5D94FD9B79C1 Q37690521-310C52B7-EE28-4F42-A6ED-116CB31FA088 Q38217766-67B37D97-2F4B-4A24-BA9A-23A1492D4838 Q38270518-84A8C28A-A6D0-4E49-BD45-06E961914A00 Q38645410-FFAE1C65-0D7D-450C-996A-B7D1B1D11B60 Q38751654-E43D4EAC-E7E9-4330-91EE-1171162E4B01 Q38862204-C5E16D21-C538-4638-A37F-5E2372984856 Q38905996-AC3F122F-C9A3-44A5-A72E-6414F36CC877 Q38939282-DCFCD708-30FA-42D7-B174-1F8DA9ACAEAB Q39077160-66C94EC1-5264-4204-AC46-2EC804EA90B1 Q39128473-8E758D7B-0B9D-42BB-96A9-5E8FAC630C57 Q39364713-F4FBA735-76DB-44C7-9904-E44653B540D5 Q39404657-B33B417C-0304-4E15-9A0B-009A0411D73B Q39730152-E6B7611D-AF75-4A04-932B-86E1B0997760 Q40236129-E2ED881E-9F84-4048-82DD-76577BA2EA2F Q40944905-831618B4-2F23-467C-984C-B1D7B26D8217 Q47790879-F7567005-5B97-4EBB-B90C-8B86D7F1927B Q48168744-2C69271C-F46F-4F1C-BFB9-4A6688D177F0 Q48314813-15E992C5-294E-4522-B10D-30B677B328E8 Q49451963-C106A9C1-94FE-46E8-B732-1504027D4942 Q50130544-BB2BCC56-BD65-4E8C-B5A9-704EE33EF846

P2860

RIPK3 as a potential therapeutic target for Gaucher's disease.

http://www.wikidata.org/entity/Q54383542

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

RIPK3 as a potential therapeutic target for Gaucher's disease.

@en

RIPK3 as a potential therapeutic target for Gaucher's disease.

@nl

type

label

RIPK3 as a potential therapeutic target for Gaucher's disease.

@en

RIPK3 as a potential therapeutic target for Gaucher's disease.

@nl

prefLabel

RIPK3 as a potential therapeutic target for Gaucher's disease.

@en

RIPK3 as a potential therapeutic target for Gaucher's disease.

@nl

P1433

Q54383542-10EF06C2-9D68-444C-B56F-7C8B0EDE3D61

P1476

Q54383542-0E180209-91E9-42E7-A7E4-8CCC21A0E281

P2093

Q54383542-0558FF14-1D10-4F10-96EC-5CF7D19BF7CF

Q54383542-57185708-0AE8-45AB-B590-B8D2B6C8C297

Q54383542-AC39985A-A488-469A-8CDF-0A6C1B6C582C

Q54383542-C2FB7867-14C9-4C4E-8964-CEED61E1A097

Q54383542-C56575CD-EC8F-4053-AE0D-6B0F89029ACC

Q54383542-E3CB4CC5-4633-4BB4-8468-30C26169CA15

P2860

Q54383542-1009D39A-14B7-4F2A-B537-2F41E846BFFA

Q54383542-207E06C0-E527-4C0E-AB00-6DBD710F8F35

Q54383542-2297C5ED-CCE5-405D-A6C5-93BC3291C61F

Q54383542-260C4B83-4162-4C03-87FE-9D3727A85AAE

Q54383542-2D13686B-6A46-4077-B935-783D46C2729D

Q54383542-2D48EC57-9561-48AC-BFC3-47A1FB9FF0BA

Q54383542-37B5D9FE-8D9E-49C7-B04D-E52DF69EAA95

Q54383542-39C2AA54-0EA8-4725-8E4D-70E0F9802F81

Q54383542-3CABD271-EA25-4824-83AA-6089CF97F945

Q54383542-48DF07B6-39BA-46E8-8FB1-5D6CB6B4E13D

P2888

Q54383542-EED03AFB-CD4D-4F49-9609-9CA881DB3CCB

P304

Q54383542-6E587F94-574E-4610-BBFF-E1F5EB4E43AC

P31

Q54383542-EB6AE695-3F61-411E-92CF-33074050E6F9

P356

Q54383542-B5B21A5D-8ADD-4A23-95DD-D21C4BC9D98B

P407

Q54383542-52713A96-95ED-4F53-AB7B-76BB030542EE

P433

Q54383542-775D2F26-B830-41D9-97FC-9782CA4D04B4

P478

Q54383542-20C08E07-980C-4083-93D4-9AE88A62A309

P50

Q54383542-32BE48F0-EAE8-47E1-BBBD-9A4763CE89C3

Q54383542-A7181B31-F522-46C7-9BBF-E6A9313FA95F

Q54383542-F306EBAD-92D6-4787-92F6-3EB599CA823B

P577

Q54383542-9044F33C-4DD0-4FF3-8856-F1A7E4653A5C

P5875

Q54383542-24DCCE44-38CE-4DA1-837A-CBC1BD7D24C0

P698

Q54383542-5B6E6E7B-78C3-4B44-ADCA-BA631816CD50

P356

P1433

Nature Medicine

P1476

RIPK3 as a potential therapeutic target for Gaucher's disease.

@en

P2093

Anna Meshcheriakova

http://www.w3.org/2001/XMLSchema#string

Einat B Vitner

http://www.w3.org/2001/XMLSchema#string

Mohammad Ali

http://www.w3.org/2001/XMLSchema#string

Ran Salomon

http://www.w3.org/2001/XMLSchema#string

Tamar Farfel-Becker

http://www.w3.org/2001/XMLSchema#string

Timothy M Cox

http://www.w3.org/2001/XMLSchema#string

P2860

Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis

Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase

cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms

Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation

The NAD-dependent deacetylase SIRT2 is required for programmed necrosis

Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis

Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism

RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis

Molecular mechanisms of necroptosis: an ordered cellular explosion

RIP3 mediates the embryonic lethality of caspase-8-deficient mice

P2888

P304

204-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3449

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Anthony H. Futerman

P577

2014-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259808415

http://www.w3.org/2001/XMLSchema#string

P698

24441827

http://www.w3.org/2001/XMLSchema#string